Ascensia Diabetes Care has expanded its partnership with Insulet (NSDQ:PODD) to include a global commercial deal.
The two companies inked a world-wide development agreement in June last year to connect Ascensia’s Contour Next One blood glucose monitor with Insulet’s next-gen Omnipod system, Omnipod Dash.
According to the terms of the non-exclusive commercial deal, Insulet plans to distribute the Contour Next One meter and test strips with the Omnipod Dash insulin delivery system.
Ascensia’s blood glucose monitor syncs via Bluetooth Low Energy with the Omnipod Dash Personal Diabetes Manager, sending a user’s blood glucose readings to the system to be used by the Dash PDM to calculate insulin doses.
“I am excited to announce this commercial agreement as the next step in our strategic alliance with Insulet. This agreement allows people with diabetes who choose Omnipod Dash to receive Ascensia’s Contour Next One meter and test strips to connect to Insulet’s pump,” Ascensia CEO Michael Kloss said in prepared remarks.
“We believe this strategic alliance with Insulet will help us to further establish ourselves as the partner of choice for blood glucose monitoring in the insulin pump sector.”
